Why the study?
Does homocysteine reduce protein C activation in cultured arterial and venous endothelial cells?
Does homocysteine reduce protein C activation in cultured arterial and venous endothelial cells?
Homocysteine reduces protein C activation by acting as a competitive inhibitor to thrombin, providing a potential mechanism for the thrombotic tendency in patients with elevated homocysteine.
May impair endothelial protein C activation in vitro; leaves open contribution to clinical thrombosis in hyperhomocysteinemia.
Elevated blood levels of homocysteine are associated with atherosclerosis and thrombotic disease. We previously reported that treatment of cultured endothelial cells with homocysteine increased endogenous factor V activity by activation of the cofactor. Because endothelial cell-associated factor Va would be regulated by the protein C mechanism, the ability of homocysteine-treated arterial and venous endothelial cells to activate protein C was investigated. Both arterial and venous endothelial cells activated protein C; 0.6 mmol/L homocysteine reduced endothelial cell protein C activation by 12%. Maximal inhibition (90%) of protein C activation occurred with 7.5 to 10 mmol/L homocysteine after 6 to 9 hours of incubation. Metabolism of homocysteine was not accelerated by cultured endothelial cells. Investigation of the mechanism(s) by which homocysteine reduced protein C activation indicated that the metabolite did not induce an inhibitor to activated protein C, but in low concentrations acted as a competitive inhibitor to thrombin. These data suggest that perturbation of the vascular endothelial cell protein C mechanism by homocysteine may contribute to the thrombotic tendency seen in patients with elevated blood levels of this metabolite.
No takes yet. Share an insight, caveat, or question.
Rodgers et al. (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: